Roivant Sciences Ltd. (ROIV) stock

ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through Q2 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30

$39.53−0.46 (-1.15%)

Close on Nov 13, 2026Market cap $28.55BP/E –Yield –

Roivant Sciences EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Roivant Sciences's EV/EBITDA was 0.7× on Jan 31, 2025.

Period	Period end	Value	Change (pts)
2025	Jan 31, 2025	0.7×	−0.1
2024	Dec 31, 2024	0.8×	–

Parsed from the XBRL in Roivant Sciences's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ROIV.

Revenue growth102.1% · median -44.6%

Operating margin-1358.1% · median -540.7%

Net margin-838.2% · median -471.3%

Advertisement
300 × 250

See a number that looks wrong?